MYC and Miyoshi myopathy: Only the drugs with activity toward CDK9 were capable of downregulating c-Myc, c-Maf and cyclin D1 in RPMI-8226 cells suggesting the pivotal role of CDK9 inhibition in SLMs anti-MM activity.